CFRA analyst Wan Nurhayati upgraded GlaxoSmithKline (NYSE: GSK) from Hold to Buy with a price target of $53.00 (from $40.00).The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE